Lymphangioleiomyomatosis

Clinics in Chest Medicine

Volumn 25, Issue 3, 2004, Pages 573-582

  Glassberg, Marilyn K ^a  

^a UNIVERSITY OF MIAMI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HORMONE; MEDROXYPROGESTERONE; OXYGEN; PROGESTERONE; RAPAMYCIN; TAMOXIFEN;

AIRWAY CONSTRICTION; BLOOD VESSEL OCCLUSION; BRAIN INJURY; CELL MATURATION; CELL PROLIFERATION; CLINICAL FEATURE; CLINICAL TRIAL; CYST; DIAGNOSTIC PROCEDURE; DISEASE ASSOCIATION; DISEASE COURSE; GENE MUTATION; GENETIC ANALYSIS; HUMAN; IDIOPATHIC DISEASE; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; LUNG BIOPSY; LUNG FUNCTION; LUNG TRANSPLANTATION; LYMPHANGIOLEIOMYOMATOSIS; NONHUMAN; OXYGEN THERAPY; PATHOPHYSIOLOGY; PATIENT; PHENOTYPE; PRIORITY JOURNAL; REVIEW; SEX DIFFERENCE; SMOOTH MUSCLE FIBER; SURVIVAL; THORAX RADIOGRAPHY; TUBEROUS SCLEROSIS;

COMORBIDITY; HUMANS; LYMPHANGIOLEIOMYOMATOSIS; PNEUMOTHORAX; RESPIRATORY FUNCTION TESTS;

EID: 4344590422     PISSN: 02725231     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccm.2004.05.003     Document Type: Review

References (65)

1. Van Stossel E. 1937 Uber muskulare cirrhose der lunge. Beitr Klin Tuberk Spezif Tuberkuloseforsch. 90:1937;432-442
2. Cavazza A., Roggeri A., Zini M., Rossi G., Zucchi L. Lymphangioleiomyomatosis associated with pulmonary metastasis from an occult papillary carcinoma of the thyroid: report of a case occurring in a patient without tuberous sclerosis. Pathol Res Pract. 198:2002;825-828
3. Chan J.K., Tsang W.Y., Pau M.Y., Tang M.C., Pang S.W., Fletcher C.D. Lymphangiomyomatosis and angiomyolipoma: closely related entities characterized by HMB-45-positive smooth muscle. Histopathology. 22:1993;445-455
4. Hancock E., Tomkins S., Sampson J., Osborne J. Lymphangioleiomyomatosis and tuberous sclerosis. Respir Med. 96:2002;7-13
5. Mark Z., Sapi Z., Meszaros Z., Strausz J. [Rare association of rare diseases: Langerhans-cell histiocytosis and lymphangioleiomyomatosis in the lung]. Orv Hetil. 142:2001;1851-1854
6. Chan A.L., Kwack S., Jones K.D., Glassberg M.K., Gherman C.R. Lymphangioleiomyomatosis and SZ alpha (1)-antitrypsin disease: a unique combination? Chest. 124:2003;763-765
7. Sullivan E.J. Lymphangioleiomyomatosis: a review. Chest. 114:1998;1689-1703
8. Oberstein E.M., Fleming L.E., Gomez-Marin O., Glassberg M.K. Pulmonary lymphangioleiomyomatosis (LAM): examining oral contraceptive pills and the onset of disease. J Womens Health. 12:2003;81-85
9. Crausman R.S., Jennings C.A., Mortenson R.L., Ackerson L.M., Irvin C.G., King T.E. Jr. Lymphangioleiomyomatosis: the pathophysiology of diminished exercise capacity. Am J Respir Crit Care Med. 153:1996;1368-1376
10. Kirchner J., Stein A., Viel K., Dietrich C.F., Thalhammer A., Schneider M., et al. Pulmonary lymphangioleiomyomatosis: high-resolution CT findings. Eur Radiol. 9:1999;49-54
11. Ryu J.H., Swensen S.J. Cystic and cavitary lung diseases: focal and diffuse. Mayo Clin Proc. 78:2003;744-752
12. Moss J., DeCastro R., Patronas N.J., Taveira-DaSilva A. Meningiomas in lymphangioleiomyomatosis. JAMA. 286:2001;1879-1881
13. Chu S.C., Horiba K., Usuki J., Avila N.A., Chen C.C., Travis W.D., et al. Comprehensive evaluation of 35 patients with lymphangioleiomyomatosis. Chest. 115:1999;1041-1052
14. Kalassian K., Berry G., Raffin T.A. Lymphangioleiomyomatosis: clinical aspects. Moss J. LAM and other disease characterized by smooth muscle proliferation. 1999;50 Marcel Dekker, New York
15. th edition:1996;McGraw Hill, New York
16. Pinkard N.B. Enlarged airspaces. Lung biology in health and disease 2000;142
17. Bonetti F., Pea M., Martignoni G., Mombello A., Columbari R., Zamboni G., et al. False-positive immunostaining of normal epithelia and carcinomas with ascites fluid preparations of antimelangna monoclonal antibody HMB45. Am J Clin Pathol. 95:1991;454-459
18. Ferrans V.J., Yu Z.X., Nelson W.K., Valencia J.C., Tatsuguchi A., Avila N.A., et al. Lymphangioleiomyomatosis (LAM): a review of clinical and morphological features. J Nippon Med Sch. 67:2000;311-329
19. Hudson A.R., Smoller B.R. Immunohistochemistry in diagnostic dermatopathology. Dermatol Clin. 17:1999;667-689. x
20. Matsui K., Takeda K., Yu Z.X., Travis W., Moss J., Ferrans V.J. Role for activation of matrix metalloproteinases in the pathogenesis of pulmonary lymphangioleiomyomatosis. Arch Pathol Lab Med. 124:2000;267-275
21. Moss J., Avila N.A., Barnes P.M., Litzenberger R.A., Bechtle J., Brooks P.G., et al. Prevalence and clinical characteristics of lymphangioleiomyomatosis (LAM) in patients with tuberous sclerosis complex. Am J Respir Crit Care Med. 164:2001;669-671
22. Sampson J.R. TSC1 and TSC2: genes that are mutated in the human genetic disorder tuberous sclerosis. Biochem Soc Trans. 31:2003;592-596
23. Castro M., Shepherd C.W., Gomez M.R., Lie J.T., Ryu J.H. Pulmonary tuberous sclerosis. Chest. 107:1995;189-195
24. Costello L.C., Hartman T.E., Ryu J.H. High frequency of pulmonary lymphangioleiomyomatosis in women with tuberous sclerosis complex. Mayo Clin Proc. 75:2000;591-594
25. Franz D.N., Brody A., Meyer C., Leonard J., Chuck G., Dabora S., et al. Mutational and radiographic analysis of pulmonary disease consistent with lymphangioleiomyomatosis and micronodular pneumocyte hyperplasia in women with tuberous sclerosis. Am J Respir Crit Care Med. 164:2001;661-668
26. Maruyama H., Ohbayashi C., Hino O., Tsutsumi M., Konishi Y. Pathogenesis of multifocal micronodular pneumocyte hyperplasia and lymphangioleiomyomatosis in tuberous sclerosis and association with tuberous sclerosis genes TSC1 and TSC2. Pathol Int. 51:2001;585-594
27. Bernstein S.M., Newell J.D. Jr., Adamczyk D., Mortenson R.L., King T.E. Jr., Lynch D.A. How common are renal angiomyolipomas in patients with pulmonary lymphangiomyomatosis? Am J Respir Crit Care Med. 152:1995;2138-2143
28. Narayanan V. Tuberous sclerosis complex: genetics to pathogenesis. Pediatr Neurol. 29:2003;404-409
29. Aicher L.D., Campbell J.S., Yeung R.S. Tuberin phosphorylation regulates its interaction with hamartin. Two proteins involved in tuberous sclerosis. J Biol Chem. 276:2001;21017-21021
30. Han S., Santos T.M., Puga A., Roy J., Thiele E.A., McCollin M., et al. Phosphorylation of tuberin as a novel mechanism for somatic inactivation of the tuberous sclerosis complex proteins in brain lesions. Cancer Res. 64:2004;812-816
31. Nellist M., van Slegtenhorst M.A., Goedbloed M., van den Ouweland A.M., Halley D.J., van der S.P. Characterization of the cytosolic tuberin-hamartin complex. Tuberin is a cytosolic chaperone for hamartin. J Biol Chem. 274:1999;35647-35652
32. Goncharova E.A., Goncharov D.A., Eszterhas A., Hunter D.S., Glassberg M.K., Yeung R.S., et al. Tuberin regulates p70 S6 kinase activation and ribosomal protein S6 phosphorylation. A role for the TSC2 tumor suppressor gene in pulmonary lymphangioleiomyomatosis (LAM). J Biol Chem. 277:2002;30958-30967
33. Potter C.J., Pedraza L.G., Xu T. Akt regulates growth by directly phosphorylating Tsc2. Nat Cell Biol. 4:2002;658-665
34. Gao X., Zhang Y., Arrazala P., Hino O., Kobayashi T., Yeung R.S., et al. Tsc tumor suppressor proteins antagonize amino-acid-TOR signaling. Nat Cell Biol. 4:2002;699-704
35. Fingar D.C., Blenis J. Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression. Oncogene. 23:2004;3151-3171
36. Kerfoot C., Wienecke R., Menchine M., Emelin J., Maize J.C. Jr., Welsh C.T., et al. Localization of tuberous sclerosis 2 mRNA and its protein product tuberin in normal human brain and in cerebral lesions of patients with tuberous sclerosis. Brain Pathol. 6:1996;367-375
37. Jozwiak S., Kwiatkowski D., Kotulska K., Larysz-Brysz M., Lewin-Kowalik J., Grajkowska W., et al. Tuberin and hamartin expression is reduced in the majority of subependymal giant cell astrocytomas in tuberous sclerosis complex consistent with a two-hit model of pathogenesis. J Child Neurol. 19:2004;102-106
38. Johnson S.R., Clelland C.A., Ronan J., Tattersfield A.E., Knox A.J. The TSC-2 product tuberin is expressed in lymphangioleiomyomatosis and angiomyolipoma. Histopathology. 40:2002;458-463
39. Smolarek T., Wessner L.L., McCormack F.X., Mylet J.C., Travis W., Henske E.P. Evidence that lymphangiomyomatosis is caused by TSC2 mutations: chromosome 16p13 loss of heterozygosity in angiomyolipomas and lymph nodes from women with lymphangiomyomatosis. Am J Hum Genet. 62:2004;810-815
40. Carsillo T., Astrinidis A., Henske E.P. Mutations in the tuberous sclerosis complex gene TSC2 are a cause of sporadic pulmonary lymphangioleiomyomatosis. Proc Natl Acad Sci U S A. 97:2000;6085-6090
41. Yu J., Astrinidis A., Henske E.P. Chromosome 16 loss of heterozygosity in tuberous sclerosis and sporadic lymphangiomyomatosis. Am J Respir Crit Care Med. 164:2001;1537-1540
42. Astrinidis A., Khare L., Carsillo T., Smolarek T., Au K.S., Northrup H., et al. Mutational analysis of the tuberous sclerosis gene TSC2 in patients with pulmonary lymphangioleiomyomatosis. J Med Genet. 37:2000;55-57
43. Sato T., Seyama K., Fujii H., Maruyama H., Setoguchi Y., Iwakami S., et al. Mutation analysis of the TSC1 and TSC2 genes in Japanese patients with pulmonary lymphangioleiomyomatosis. J Hum Genet. 47:2002;20-28
44. Pan L.H., Ito H., Kurose A., Yamauchi K., Inoue H., Sawai T. Pulmonary lymphangioleiomyomatosis: a case report with immunohistochemical details and DNA analysis. Tohoku J Exp Med. 199:2003;119-126
45. Strizheva G.D., Carsillo T., Kruger W.D., Sullivan E.J., Ryu J.H., Henske E.P. The spectrum of mutations in TSC1 and TSC2 in women with tuberous sclerosis and lymphangiomyomatosis. Am J Respir Crit Care Med. 163:2001;253-258
46. Boehler A., Speich R., Russi E.W., Weder W. Lung transplantation for lymphangioleiomyomatosis. N Engl J Med. 335:1996;1275-1280
47. Nine J.S., Yousem S.A., Paradis I.L., Keenan R., Griffith B.P. Lymphangioleiomyomatosis: recurrence after lung transplantation. J Heart Lung Transplant. 13:1994;714-719
48. O'Brien J.D., Lium J.H., Parosa J.F., Deyoung B.R., Wick M.R., Trulock E.P. Lymphangiomyomatosis recurrence in the allograft after single-lung transplantation. Am J Respir Crit Care Med. 151:1995;2033-2036
49. Pechet T.T., Meyers B.F., Meyers B.F., Guthrie T.J., Battafarano R.J., Trulock E.P., Cooper J.D., et al. Lung transplantation for lymphangioleiomyomatosis. J Heart Lung Transplant. 23:2004;301-308
50. Karbowniczek M., Astrinidis A., Balsara B.R., Testa J.R., Lium J.H., Colby T.V., et al. Recurrent lymphangiomyomatosis after transplantation: genetic analyses reveal a metastatic mechanism. Am J Respir Crit Care Med. 167:2003;976-982
51. Johnson S.R., Tattersfield A.E. Clinical experience of lymphangioleiomyomatosis in the UK. Thorax. 55:2000;1052-1057
52. Baldi S., Papotti M., Valente M.L., Rapellino M., Scappaticci E., Corrin B. Pulmonary lymphangioleiomyomatosis in postmenopausal women: report of two cases and review of the literature. Eur Respir J. 7:1994;1013-1016
53. Wilson A.M., Slack H.L., Soosay S.A., Taylor T., Carey F.A., Grove A., et al. Lymphangioleiomyomatosis. A series of three case reports illustrating the link with high oestrogen states. Scott Med J. 46:2001;150-152
54. Weinans M.J., van Loon A.J. A diagnosis of lymphangioleiomyomatosis in a pregnant woman presenting with a retroperitoneal mass. Br J Obstet Gynaecol. 106:1999;747-748
55. Yockey C.C., Riepe R.E., Ryan K. Pulmonary lymphangioleiomyomatosis complicated by pregnancy. Kans Med. 87:1986;277-278
56. Yano S. Exacerbation of pulmonary lymphangioleiomyomatosis by exogenous oestrogen used for infertility treatment. Thorax. 57:2002;1085-1086
57. Logginidou H., Ao X., Russo I., Henske E.P. Frequent estrogen and progesterone receptor immunoreactivity in renal angiomyolipomas from women with pulmonary lymphangioleiomyomatosis. Chest. 117:2000;25-30
58. Matsui K., Takeda K., Yu Z.X., Valencia J.C., Travis W., Moss J., et al. Downregulation of estrogen and progesterone receptors in the abnormal smooth muscle cells in pulmonary lymphangioleiomyomatosis following therapy. An immunohistochemical study. Am J Respir Crit Care Med. 161:2000;1002-1009
59. Finlay G.A., York B., Karas R.H., Fanburg B.L., Zhang H., Kwiatkowski D.J., et al. Estrogen-induced smooth muscle cell growth is regulated by tuberin and associated with altered activation of PDGFR-beta and ERK-1/2. J Biol Chem. 274:2004;2314-2322
60. Eliasson A.H., Phillips Y.Y., Tenholder M.F. Treatment of lymphangioleiomyomatosis. A meta-analysis. Chest. 96:1989;1352-1355
61. Oh Y.-M., Mo E.K., Jang S.H., Yoo C.G., Kim Y.W., Seo J.W., et al. Pulmonary lymphangioleiomyomatosis in Korea. Thorax. 54:1999;618-621
62. Kitachi M., Nishimura K., Itoh H., Izumi T. Pulmonary lymphangioleiomyomatosis: a report of 46 patients including a clinicopathologic study of prognostic factors. Am J Respir Care Med. 151(2 pt 1):1995;527-533
63. Urban T., Lazor R., Lacronique J., Murris M., Labrune S., Valeyre D., et al. Pulmonary lymphangioleiomyomatosis. A study of 69 patients. Group d'Etudes et de Recherche sur les Maladies "Orphelines" Pulmonaires (GERM"O" P). Medicine. 78:1999;321-337
64. Lipman M.C.I., Dubois R.M. Clinical experience with lymphangioleiomyomatosis in United Kingdom. Moss J. LAM and other disease characterized by smooth muscle proliferation. 1999;35 Marcel Dekker, New York
65. Roman A., Aristizabal D., Pallisa E., Majo J., Iscar M., Monforte V., et al. Lymphangioleimyomatosis: study of 15 patients. Med clin (Barc). 115(3):2000;98-102